In the next issue of Pharma Technology Focus, we explore the potential of ketamine-based products following the US FDA’s vote to back Johnson & Johnson’s depression drug esketamine and track the life and times of the European Medicines Agency as the flag goes down on the organisation’s London headquarters.
We also examine the launch of Australian medical cannabis firm Althea in the UK and find out what the pharma and biotech industries could learn from an open-science approach to drug development
Plus, we take a look at the research from Toronto's Centre for Addiction and Mental Health and examine other treatments targeting memory loss. Finally, we speak to the team behind RUNLABS, a start-up dedicated to providing laboratory space and accelerator services to new biotech firm, to find out what services these fledgling businesses need during their early years.
Editor | Eloise McLennan
Group Editor | Susanne Hauner
Commissioning Editor | Daniel Garrun
Writers | Abi Millar, Charlotte Edwards, Chris Lo, Allie Nawrat, Sally Turner, Catherine Gambert
Magazine Designer | Marzia Del Gaone
Graphic Designers | Paulius Zutautas, Kate Cuntapay, Anett Arc, Sara Basto, Ashley McPherson, Tyrrell Lowe, Noemi Balint
Lead Designer | John Hammond
Digital Publishing Director | Duncan West
Sales Manager | Nimai Amin
+44 (0) 207 936 6453
Media Partnership Enquiries | Susanne Hauner
Pharma Technology focus is powered by h5mag
read past issues of pharma technology focus HERE
Pharma Technology Focus is a product of Net Resources International. Copyright 2018 Net Resources International, a trading division of Kable Intelligence Limited. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.